7月23日 - ** 药物开发商Arrowhead ARWR.O的股价在收盘前上涨4%至15.50美元
** 公司表示，预计到今年年底仍将从合作伙伴 Sarepta Therapeutics SRPT.O那里获得 3 亿美元的里程碑付款 (link)
** Sarepta 股价盘前下跌 ~2%，报 13.40 美元
** SRPT 并未表示不打算履行其财务义务，Arrowhead 表示
** 作为去年协议的一部分，Arrowhead 许可 Sarepta 使用其几种疗法，包括四种早期候选疗法
** ARWR 获得了 5 亿美元的预付款，并有资格从 Sarepta 获得多达 100 亿美元的里程碑付款，涉及多种疗法
** 截至上次收盘，ARWR 下跌 23.4%，SRPT 下跌约 89
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.